Glaukos Corporation: Truist Securities raises target price to $255 from $215
GKOS•Truist Securities raised its target price for Glaukos Corporation to $255 from $215.
Related News
Mira Pharmaceuticals' SKNY-1 reduces weight in obese mice in pilot study
MIRA•
Microsoft reportedly looks to raise at least $25 billion from US bond sale
MSFT•
Enviri's Harsco Environmental secures 10-year contract renewal with Egypt's EZS
NVRI•
FDA clears Eloxx's Exaluren for Phase 2 trial in ADPKD
ELOX•
Rigel Pharmaceuticals schedules third-quarter results conference call
RIGL•